CTX-001 (Central Therapeutics)

CTX-001 is an investigational bispecific antibody being developed by Central Therapeutics for the treatment of various allergic diseases, including allergic asthma, chronic spontaneous urticaria, food allergy, and seasonal rhinitis. Incubated by ADAR1 Partners and announced in 2025, the therapy is designed to be disease-modifying with the potential to provide a functional cure rather than temporary symptom management. While its specific molecular targets remain undisclosed, CTX-001 is currently in the preclinical/IND-enabling stage, with an estimated timeline of 18 months to enter clinical trials as of early 2025. It represents a key asset in Central Therapeutics' pipeline of inflammation and immunology (I&I) biologics, aimed at addressing high-potential markets with an efficient discovery pathway.